Europe Analysis

Pages

Industry Trend Analysis - Multiple Blockbuster IBD Market Is On The Horizon - APR 2017

With no drugs yet providing cures for ulcerative colitis or Crohn's disease, inflammatory bowel disease remains a therapy area with blockbuster potential for any drugs that can tackle these conditions effectively. Products under development include biosimilars and innovative products, and as understanding of IBD increases, so too this market will develop. With Entyvio already marketed, Takeda...

READ FULL ARTICLE

Industry Trend Analysis - Takeda Investment Highlights Growing Confidence In TiGenix - MAR 2017

Takeda's equity investment in TiGenix, coinciding with a recent US IPO, highlights a growing confidence in TiGenix and its lead product, Cx601, for treating complex perianal fistulas in Crohn's disease. Although Cx601 has yet to be commercialised, and TiGenix has yet to make a profit, development of the drug is progressing smoothly. Should Cx601 be approved and launched in the US and the EU, it...

READ FULL ARTICLE

Pages